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Purpose: In this study, we analyzed a cohort of children with chronic graft-versus-
host disease (GvHD) according to the NIH consensus classification (NCC) in order 
to observe whether global assessment at diagnosis correlates with GvHD-specific 
endpoints. We then studied the clinical course of these patients, specifically with re-
gards to episodes of GvHD exacerbation requiring treatment escalation. Materials 
and Methods: Recipients of either allogeneic bone marrow transplantation (BMT) 
or peripheral blood stem cell transplantation (PBSCT) from January 2006 to August 
2008 at the Department of Pediatrics, The Catholic University of Korea were evalu-
ated for chronic GvHD, which was diagnosed according to the NCC. The course of 
chronic GvHD in these patients was then followed. Results: Of 59 evaluable pa-
tients, 23 developed chronic GvHD for a cumulative incidence of 39.3%. Upon mul-
tivariate analysis, previous acute GvHD (≥grade II) had a significant impact on 
chronic GvHD incidence. With a median duration of systemic treatment for chronic 
GvHD of 501 days, no significant relationship was found between initial global se-
verity of chronic GvHD and either duration of immunosuppressive treatment or final 
clinical response to treatment. Fifteen patients (65%) experienced at least one epi-
sode of chronic GvHD exacerbation during the period of follow-up, with a median 
of four exacerbations in the subgroup of patients who experienced such events. Lung 
GvHD resulted in the highest number of exacerbations per diagnosed patient, fol-
lowed by oral GvHD. Conclusion: Analysis of this small cohort indicates that global 
assessment as proposed by the NCC may have limited correlations with GvHD-spe-
cific endpoints, possibly due to the favorable response of children to treatment.
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INTRODUCTION
   
The multitude of manifestations of chronic graft-versus-host disease (GvHD) has 
made its accurate diagnosis and classification a difficult task. The initial classifica-
tion of chronic GvHD into limited and extensive forms1 was subsequently revised 
into a scheme that further elaborated on the types of organ involvement that char-
acterize these subtypes.2 In 2005, the NIH reported a consensus criteria (NCC) for Jae Wook Lee, et al.
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cohort of pediatric recipients of either allogeneic bone mar-
row (BMT) or G-CSF mobilized peripheral blood stem cell 
transplantation (PBSCT) to observe the prognostic potential 
of the NCC, especially with regards to the global severity rat-
ing. Specifically, we assessed whether global severity at diag-
nosis correlates with GvHD-specific endpoints such as dura-
tion of systemic immunosuppressive treatment (IST), and 
overall clinical response to IST at the last follow-up. Correla-
tion between global severity at diagnosis and GvHD-specific 
endpoints was shown in one adult-based study.5 In contrast to 
these findings, our hypothesis was that initial severity as mea-
sured by the NCC has limited prognostic value with regards 
to these GvHD-specific endpoints in children. Second, we at-
tempted to characterize in detail the clinical course of chronic 
GvHD diagnosed in our cohort of pediatric patients, especial-
ly GvHD aggravation during the period of systemic IST.
MATERIALS AND METHODS
　　　
Chronic GvHD cohort
Consecutive pediatric recipients of either allogeneic BMT 
or PBSCT from January 2006 to August 2008 at the De-
partment of Pediatrics, The Catholic University of Korea, 
Seoul, Korea were evaluated for chronic GvHD. Only pa-
tients who survived the initial 100 days after transplantation 
were included in this evaluation. In order to create a unified 
cohort for the study of chronic GvHD, recipients of addi-
tional stem cells, in the form of donor lymphocyte infusion 
or booster infusion, were excluded, as were recipients of G-
CSF mobilized bone marrow. The study design received 
approval from the institutional review board of Seoul Saint 
Mary’s Hospital, The Catholic University of Korea.
Overall, among the 59 patients included in the initial 
evaluation, chronic GvHD as specified by the NCC was di-
agnosed in 23 patients at a mean duration of 6.7 months 
(range: 1.8-23.8 months) after HSCT for a four-year cumu-
lative incidence of 39.3%. The median duration of follow-
up from diagnosis of chronic GvHD was 26.1 months 
(range: 8.1-45.6 months). The pertinent clinical characteris-
tics of this chronic GvHD cohort are shown in Table 1.
Transplantation procedure and acute GvHD
Donor and recipient pairs were fully matched by HLA-A, 
B and DR at the molecular level, and both related and unre-
lated transplantations were included in the study cohort.   
The patients received either TBI-based conditioning regi-
the diagnosis and staging of chronic GvHD, taking into ac-
count novel manifestations of chronic GvHD in the setting 
of post-transplantation immunomodulation,3 and a key ele-
ment of this NCC diagnosis and staging is a global severity 
rating of chronic GvHD based on the extent of each organ’s 
involvement. Since the announcement of this most recent 
diagnostic scheme, several authors have reported on a ret-
rospective reclassification of chronic GvHD utilizing the 
NCC, based mostly on the adult hematopoietic stem cell 
transplantation (HSCT) population, with conflicting results 
on the prognostic utility of the NCC.4-6 Published reports on 
the application of the NCC in the pediatric HSCT popula-
tion are lacking, yet the need for a standard and valid diag-
nostic scheme is urgent, considering the importance of ac-
curate reporting of chronic GvHD severity at diagnosis and 
throughout treatment.
In this study, our objectives were twofold: first, we retro-
spectively reclassified chronic GvHD according to NCC in a 
Table 1. Chronic GvHD Cohort
Study cohort (n=23) (%)
Age at transplantation
    Median (yrs) 12.3 (range, 1.7-18.8)
Gender
    Male/Female 15 (65)/8 (35)
Diagnosis
    ALL/AML   7 (30)/10 (44)
    CML/JMMoL   2 (9)/1 (4) 
    SAA/FA   1 (4)/2 (9)
Disease status
    Standard*/High 23 (100)/0 (0)
Donor type
    Sibling/Unrelated 11 (48)/12 (52)
Conditioning regimen
    TBI based/Non-TBI based   7 (30)/16 (70)
GvHD prophylaxis
     CS+MTX(4)
†/CS+MTX(0-3)
‡ 15 (65)/8 (35) 
Donor age
    Median (yrs) 23 (range, 8-46)
Donor-recipient gender
    Female-male/Others   6 (26)/17 (74)
ABO mismatch
    Match/Mismatch 10 (44)/13 (57)
Acute GvHD
    Grades 0-1/Grades II-IV   5 (22)/18 (78)
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, 
chronic myeloid leukemia; JMMoL, juvenile myelomonocytic leukemia; 
SAA, severe aplastic anemia; FA, Fanconi anemia; GvHD, graft-versus-
host disease.
*standard risk: AML in CR1, ALL in≤CR2, CML in CP.
†cyclosporine+4 scheduled doses of mini-methotrexate.
‡cyclosporine alone, or less than 4 scheduled doses of mini-methotrexate.NIH Criteria for Chronic GvHD in Children
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persistent acute GvHD as chronic GvHD,9 patients lacking 
diagnostic GI criteria and complaining of common GI symp-
toms such as vomiting, diarrhea and weight loss were not 
scored as having chronic GI GvHD unless a biopsy speci-
men proved otherwise.
Scoring of hepatic GvHD may also lend itself to inaccu-
racy as the NCC provides neither diagnostic nor distinctive 
criteria for chronic liver GvHD, and scoring of liver in-
volvement is based on elevation of serum bilirubin or liver 
enzymes, the etiology of which may be multifactorial.10 A 
transient elevation of liver enzymes of greater than five 
times the upper normal limit is sufficient for a score of 3 
and hence, classification as severe chronic GvHD in a pa-
tient, even if other physical findings that are more diagnos-
tic for chronic GvHD are of mild severity. Yet, hepatic in-
volvement may be common enough to have a significant 
impact on the severity rating of many of these patients. A liv-
er biopsy may aid in diagnosing chronic liver GvHD with 
greater certainty, but such a biopsy was not undertaken in 
the cohort of patients. In order to resolve this problem, sever-
ity rating was done for each patient in two ways, both includ-
ing and without the organ score for hepatic involvement.
Chronic GvHD study endpoints
Two endpoints were used in this study to decide upon the fi-
nal outcome of chronic GvHD: duration of systemic IST, and 
overall clinical status of chronic GvHD at last follow-up.
The duration of systemic IST for chronic GvHD, defined 
from the date of chronic GvHD diagnosis to the end of sys-
temic IST, was calculated for each patient. Then, the NCC 
global severity rating at chronic GvHD diagnosis was eval-
uated as a potential prognostic factor for predicting discon-
tinuation of systemic IST. Attempts were made to taper and 
stop systemic IST within 18 months of initiation if the pa-
tient showed resolution of signs and symptoms.
The duration of systemic IST may not reflect the actual sta-
tus of chronic GvHD at the last follow-up as treatment may 
continue despite clinical improvement of chronic GvHD 
signs and symptoms. For a more direct indication of chron-
ic GvHD status, each patient’s chronic GvHD at the last 
follow-up was classified as follows: ‘resolved’, indicating 
eradication of all signs and symptoms of chronic GvHD 
with systemic IST stopped; ‘controlled’, indicating improved 
condition with continued or tapered IST; and ‘persistent’, 
representing continued signs and symptoms of chronic 
GvHD, or aggravation at last follow-up despite treatment.   
Patient death that was directly related to chronic GvHD 
mens (total body irradiation, cytarabine, cyclophospha-
mide) or non-TBI-based regimens (busulfan, cyclophos-
phamide; busulfan, etoposide, cyclophosphamide, anti-
thymocyte globulin (ATG); busulfan, fludarabine±ATG; 
fludarabine, cyclophosphamide, ATG). GvHD prophylaxis 
included either cyclosporine with 4 scheduled doses of 
mini-dose methotrexate or cyclosporine alone. Administra-
tion of min-dose methotrexate was withheld with the devel-
opment of mucositis requiring analgesia.
The severity and extent of acute GvHD were graded ac-
cording to previous consensus criteria.7 With regards to the 
temporal pattern of acute GvHD onset, delayed onset acute 
GvHD (after day 100) as characterized in the NCC was re-
corded in an attempt to fully classify chronic GvHD into 
the classic chronic GvHD and overlap syndrome subtypes.
Diagnosis and classification of chronic GvHD
Diagnosis   
Retrospective diagnosis of chronic GvHD was based strict-
ly on the NCC. For the diagnosis of chronic GvHD in organs 
that could prove more problematic, lung GvHD was diag-
nosed without a biopsy if the patient complained of symp-
toms such as cough and dyspnea, the radiologic findings on 
the chest computed tomography were consistent with air 
trapping without overt areas of consolidation, and the pa-
rameters on the pulmonary function test indicated an ob-
structive pattern of lung disease. Overall, in the diagnosis of 
chronic lung GvHD, efforts were made to differentiate bron-
chiolitis obliterans syndrome from bronchiolitis obliterans or-
ganizing pneumonia.8
Diagnostic criteria for chronic GvHD of the GI tract were 
limited to esophageal webs or strictures of the esophagus, 
and other more common symptoms such as vomiting and 
diarrhea did not qualify for a diagnosis of chronic GvHD.
Also, as outlined in the NCC, hyperbilirubinemia or ele-
vation of AST, ALT or other liver parameters alone were 
not sufficient for the diagnosis of chronic GvHD.
Severity of chronic GvHD
After diagnosis of chronic GvHD, organ-specific scoring 
and severity assignment as “mild”, “moderate”, and “se-
vere”, as outlined in the NCC, were done for each patient.
For strict classification of chronic GvHD, additional rules 
were implemented for the scoring of GI tract GvHD and 
hepatic GvHD. In light of the NCC’s classification of a de-
layed type of acute GvHD, and the potential to misdiagnose Jae Wook Lee, et al.
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univariate study included previous acute GvHD of grade II 
or above (p<0.001), patient age (p=0.044), and underlying 
disease (p=0.089) (Table 2). However, upon multivariate 
analysis, only preceding acute GvHD of grade II or above 
proved to have a significant impact on chronic GvHD inci-
dence (HR 5.79, 95% CI 2.06-16.24, p=0.001).
Diagnosis and classification of chronic GvHD
Diagnosis 
The most common organ for diagnosis of chronic GvHD 
was the oral cavity (N=15, 65%), followed by the skin (N=3, 
13%), lungs (N=3, 13%) and eyes (N=2, 9%). At diagnosis, 
one patient showed signs consistent with overlap syndrome 
(diagnosis of ocular GvHD combined with persistent acute 
skin GvHD), while the others were classified as classic 
chronic GvHD.
Global severity at diagnosis
Initial global severity was evaluated in all patients both 
with and without consideration of liver GvHD. With a strict 
application of NCC and eliminating potential liver involve-
ment unconfirmed by biopsy, summation of initial global 
severity resulted in 14 patients with mild (61%), six patients 
with moderate (26%) and three patients with severe chronic 
GvHD (13%). Inclusion of liver function abnormalities at 
diagnosis as a manifestation of chronic GvHD led to five 
patients with mild chronic GvHD being reclassified as hav-
ing moderate chronic GvHD, resulting in nine patients with 
mild (39%), 11 with moderate (48%) and three with severe 
chronic GvHD (13%).
Global severity at diagnosis and chronic GvHD 
prognostic parameters
Duration of systemic IST
The median duration of systemic IST for the cohort was 
501 days (range: 151-1,368). Sixteen of the 23 patients 
(70%) had systemic IST stopped at last follow-up for a prob-
ability of systemic IST withdrawal at three years of 68.7% 
(Fig. 1A). No significant relationship was found between 
initial global severity of chronic GvHD and duration of sys-
temic IST (p=0.617) (Fig. 1B). Similarly, a second assess-
ment of initial global severity that included possible hepatic 
GvHD did not alter the lack of association between initial 
GvHD severity and duration of systemic IST (p=0.647) 
(Fig. 1C).
was also recorded. Again, the NCC global severity rating at 
chronic GvHD diagnosis was assessed as a prognostic fac-
tor for these definitions of chronic GvHD status.
Course of systemic IST for chronic GvHD
The number of organs involved and the actual sites of chron-
ic GvHD for each patient during the course of systemic IST 
were recorded. Medications administered as systemic IST, 
first-line therapy or otherwise, were also summarized.
An important event during the course of chronic GvHD 
treatment is an increase in the dose of systemic IST, the ad-
dition of other immunosuppressive agents to those given 
previously, or the reinstitution of systemic IST after previ-
ous withdrawal due either to aggravation of chronic GvHD 
signs and symptoms or lengthy persistence without waning 
despite treatment. Such ‘exacerbation’ of chronic GvHD re-
quiring strengthened systemic IST have been reported to 
show significant associations with survival endpoints.11,12   
The number of such exacerbations, and the organs in which 
these exacerbations occurred were analyzed in each patient. 
Statistical analysis
The following factors were analyzed for possibly contribu-
tingto chronic GvHD incidence using a Cox proportional 
hazards regression model: age of patient and donor, gender, 
underlying disease, donor type, cell source, donor-recipient 
sex mismatch, HLA-C mismatch, ABO mismatch, condi-
tioning regimen, GvHD prophylaxis, and preceding acute 
GvHD of grade II or above. Risk factors for chronic GvHD 
incidence with a p value of <0.1 on univariate study were 
selected for multivariate analysis. Overall incidence of chron-
ic GvHD and probability of systemic IST withdrawal were 
calculated using a cumulative incidence function with death 
as a competing risk event. Comparisons of the probability 
of systemic IST withdrawal according to the initial chronic 
GvHD severity were done using Gray’s test. Correlations 
between initial chronic GvHD severity and clinical response 
to IST at the last follow-up were done using Fisher’s exact 
test. The significance level was set at p<0.05. Statistical 
analysis was done on R package, version 2.10.1 (available 
at http://CRAN.R-project.org).
RESULTS
 
Chronic GvHD risk factors
Important risk factors for chronic GvHD development on NIH Criteria for Chronic GvHD in Children
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toms with continued or tapered systemic IST. Only two pa-
tients (9%) had persistent chronic GvHD at last follow-up, 
due to skin and oral GvHD respectively, while GvHD-relat-
ed mortality occurred in another two patients (9%).
Response to IST at last follow-up
At the last follow-up, 16 patients (70%) showed resolution 
of chronic GvHD with discontinuation of systemic IST, and 
three patients (13%) had control of GvHD signs and symp-
Table 2.  Univariate Study of Risk Factors for Chronic GvHD Incidence
Patients Events p value
Patient age (yrs) 0.044
    <10/≥10 30/29     8/15
Gender 0.457
    Male/Female 44/15 15/8
Disease 0.089
    Malignancy/Non-malignancy 43/16 20/3
Donor type 0.332
    Sibling/Unrelated 22/37   11/12
Cell source 0.105
    BM/PBSC 10/49     1/22
Conditioning regimen 0.814
    TBI based/Non-TBI based 19/40     7/16
GvHD prophylaxis 0.730
    CS+MTX (4)*/CS+MTX (0-3)
† 40/19 15/8
Donor age
    ≤15/ (>15 and <30) 18/21   9/6 0.171
    ≤15/≥30 18/20   9/8 0.810
Donor-recipient sex 0.891
    Female-male/Others 18/41     6/17
HLA-C 0.106
    Match
‡/Mismatch 43/16 15/8
ABO match 0.636
    Match/Mismatch 24/35   10/13
Preceding acute GvHD <0.001
    Grades 0-I/Grades II-IV 31/28     5/18
GvHD, graft-versus-host disease; BM, bone marrow; PBSC, peripheral blood stem cell; TBI, total body irradiation; CS, cyclosporine; 
MTX, methotrexate.    
*cyclosporine+4 scheduled doses of mini-methotrexate.
†cyclosporine alone, or less than 4 scheduled doses of mini-methotrexate.
‡Match of HLA-C at the allele level.
Fig. 1. (A) Probability of withdrawal of systemic IST. (B) Probability of withdrawal of systemic IST according to initial global severity of chronic GvHD. (C)
Probability of withdrawal of systemic IST according to initial global severity of chronic GvHD (with inclusion of hepatic GvHD). GvHD, graft-versus-host disease.
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Chronic GvHD exacerbation
Overall, 57 episodes of chronic GvHD exacerbation requir-
ing strengthened systemic IST occurred throughout the fol-
low-up period. Of these 57 episodes, 41 (72%) were treated 
by increasing the dosage of the previously administered 
IST, four (7%) were treated by adding another immunosup-
pressive agent to the previous regimen, 11 (19%) were treat-
ed by reinitiating systemic IST that had been stopped, and 
one (2%) was treated by both increasing the dosage of the 
previous IST and adding a second medication to the regimen.   
Fifteen patients (65%) experienced at least one episode 
of chronic GvHD exacerbation during the period of follow-
up. In these patients, the median number of chronic GvHD 
exacerbations was four episodes (range: 1-10). With regards 
to the organ in which chronic GvHD exacerbation occurred, 
the oral cavity was the most common organ of exacerbation 
with 35 episodes, followed by the lung with 13 episodes, 
the skin with nine episodes, and the eye with three. Howev-
er, when this crude number of total exacerbation episodes 
per organ was adjusted for the number of patients who ex-
perienced chronic GvHD in that specific organ, lung GvHD 
showed the highest frequency of exacerbation, with 2.2 ex-
acerbations per patient, followed by oral GvHD with 1.6.
Clinical course of patients with chronic lung GvHD
The course of lung GvHD, which resulted in the highest 
number of exacerbations per patient, was analyzed as a sub-
set (Table 4). All six patients with lung GvHD were 10 years 
old or older at the time of HSCT, had underlying malignan-
cy, were recipients of PBSCT, and had experienced prior 
acute GvHD. At the last follow-up, two patients had resolu-
tion of lung GvHD (withdrawal of systemic IST), three pa-
tients had control of lung GvHD, and one patient, who had 
chronic GvHD involvement in five other organs, died. Sys-
temic IST was comprised of steroids+cyclosporine in five 
patients, while one patient also received mycophenolate 
mofetil for 10 months. Other supportive systemic agents in-
cluded macrolide antibiotics as anti-inflammatory agents, 
xanthine derivatives, and β2-agonists, while inhaled ste-
roids and bronchodilators were also administered.
DISCUSSION
   
Although undertaken with a small cohort of patients, this 
study has significance because it adds to the limited body of 
research on the application of the NCC to children with 
No significant correlation was noted between initial se-
verity at onset of chronic GvHD (without consideration of 
possible hepatic GvHD) and response to IST at the last fol-
low-up (p=0.098) (Table 3). A similar lack of correlation 
was also found between the initial severity of chronic GvHD 
including assessment of hepatic GvHD, and final response 
to IST (p=0.277).
Clinical course of chronic GvHD
Overall organ involvement
After initial diagnosis, the median number of organs involved   
with chronic GvHD for each patient throughout the period of 
follow-up was three (range: 1-6). Oral GvHD was the most 
common manifestation (n=22), followed by skin (n=14), liver 
(n=12), eye (n=10), lung (n=6), and joints (n=1) (Fig. 2).
Treatment of chronic GvHD
Systemic IST included steroids±calcineurin inhibitor in 22 
patients (96%). Sixteen patients were treated with steroids 
and cyclosporine, five were given steroids only, and one pa-
tient received steroids and cyclosporine alternate with ta-
crolimus. Only one patient (4%) was treated with a second-
line immunosuppressive agent for chronic GvHD: steroids 
and cyclosporine combined with mycophenolate mofetil.
Table 3. Response to Systemic IST at Last Follow-up Ac-
cording to NCC Global Severity at Onset
Current status
Severity at onset
Mild Moderate Severe
Resolved 11 4 1
Controlled   0 2 1
Persistent   2 0 0
Death   1 0 1
Total 14 6 3
IST, immunosuppressive treatment.
Fig. 2. Chronic GvHD organ involvement throughout the follow-up period. 
GvHD, graft-versus-host disease.
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tient, treatment consisted of first line IST (steroid±calcineurin 
inhibitor), further emphasizing the relatively positive response 
to treatment of chronic GvHD in this cohort of children.
The median duration of systemic IST in our cohort was 
501 days. Two previous studies on a cohort that included 
adult HSCT recipients reported median systemic IST dura-
tions of 272 days15 and 23 months,16 but an accurate com-
parison with our study may not be possible due to the differ-
ent lengths of follow-up after diagnosis of chronic GvHD.  
Notably, 65% of patients experienced at least one exacer-
bation of chronic GvHD necessitating systemic IST escala-
tion, with a median of four exacerbations in the subgroup 
of patients with such an event. Considering that a maximum 
of three such “flare-ups” per patient were documented in 
one adult patient-based study,11 the number of exacerba-
tions per child is considerable and may represent attempts 
to minimize steroid administration. Consistent with its poor 
prognosis, lung GvHD resulted in the largest number of 
such exacerbations when adjusted for the number of pa-
tients with site-specific involvement. However, in our cohort, 
despite the high frequency of exacerbations, all but one pa-
tient with lung GvHD had either resolved or controlled 
symptoms at the last follow-up, with first line IST as the 
mainstay of treatment.
After lung GvHD, oral GvHD resulted in the most exac-
erbations per diagnosed patient. This result is perhaps not 
surprising considering that the oral cavity was responsible 
for the greatest number of initial chronic GvHD diagnoses, 
as well as being the most commonly involved organ in over-
all chronic GvHD. However, the frequency with which oral 
GvHD was encountered also emphasizes the need to mini-
chronic GvHD, as well as outlining in detail the clinical 
course and response to systemic IST in children, especially 
with regards to GvHD exacerbation requiring IST incre-
mentation.
With regards to risk factors for chronic GvHD incidence, 
only antecedent acute GvHD of grade II or above proved to 
have a significant impact on multivariate analysis. Previous 
studies have shown that variables such as older patient age 
and malignant disease also act as significant risk factors,13,14 
and our results emphasize the pivotal role of previous acute 
GvHD in subsequent chronic GvHD incidence. Also, upon 
diagnosis of chronic GvHD, overlap syndrome as proposed 
by the NCC was observed only in one patient, in contrast to 
studies including adult patients in which this GvHD entity 
accounted for a much greater proportion of post-day 100 
GvHD.4,5
One important classification proposed by the NCC is a 
global assessment of GvHD based on the severity of involve-
ment in each organ. Our study shows that such a global as-
sessment at initial diagnosis of chronic GvHD has prognos-
tic correlations with neither duration of systemic IST, which 
is a commonly used endpoint in the study of chronic GvHD, 
nor with the overall response to systemic IST at the end of 
follow-up, a parameter that was defined specifically in this 
study. In the pediatric HSCT population, the prognostic utili-
ty of the boundaries of global assessment may be blurred 
by the more favorable outcome of chronic GvHD in children 
as compared to adults, which was confirmed in our study in 
which 83% of patients had either resolution of chronic 
GvHD with discontinuation of systemic IST, or improved 
symptoms with continued systemic IST. In all but one pa-
Table 4. Clinical Course of Patients with Lung GvHD*
Patient #9 Patient #10 Patient #14 Patient #15 Patient #17 Patient #21
Age 14 12 13 13 13 10
Sex F M M M M M
Primary disease AML ALL AML AML ALL CML
Initial NIH severity Severe Moderate Moderate Mild Severe Severe
Time to lung GvHD
  diagnosis (months) 8.6 46.7 1.8 19.9 4.3 13.5
FEV1 at diagnosis (%) 60 NA NA 28 73 NA
FEV1/FVC at diagnosis (%) 87 NA NA 44 101 NA
 Total no. of organs
   with chronic GvHD 1 5 3 4 3 6
 Length of systemic
  IST (days) 155 1,368 151 1,138 1,038 527
Lung GvHD status Resolved Controlled Resolved Controlled Controlled Death
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; FEV1, forced expiratory volume in 
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mize systemic IST escalation as a response to GvHD ag-
gravation, possibly through local therapeutic measures such 
as topical steroids and calcineurin inhibitors.17
Although more than 80% of the chronic GvHD cohort 
had either resolution or control of symptoms at the last fol-
low-up, complications resulting from systemic IST remain 
an important issue. Twelve patients (52%) were diagnosed 
with either osteopenia or osteoporosis on post-transplanta-
tion bone densitometry. Other endocrine problems such as 
growth hormone deficiency and gonadal deficiency were 
also diagnosed. Long term evaluation of such problems re-
mains a critical part of chronic GvHD care, especially in 
the pediatric setting.
One significant limitation of our data is the diagnostic un-
certainty of chronic hepatic GvHD due to lack of biopsy cor-
roboration. However, the NCC does not outline criteria for 
the diagnosis of chronic GvHD through hepatic involvement 
alone, and a diagnosis requires distinction from acute GvHD. 
Hence, evaluation of global severity was done both with and 
without incorporation of possible chronic hepatic GvHD for 
a strict application of the NCC. Diagnosis of lung GvHD 
also proved problematic, as none of our patients deemed to 
have pulmonary involvement had undergone lung biopsy. 
Another important limitation of our study was the small 
number of children that formed the chronic GvHD cohort; 
inclusion of more patients may have led to greater statistical 
significance than can be currently extrapolated. The NCC 
should, therefore, be given further evaluation in a larger co-
hort of children with chronic GvHD.
In conclusion, our evaluation of the NCC found the glob-
al assessment to have limited prognostic correlation with 
valid chronic GvHD endpoints such as duration of systemic 
IST, possibly due to the comparably favorable clinical course 
of pediatric chronic GvHD. Although the majority of patients 
in the cohort had chronic GvHD controlled at last follow-up, 
multiple exacerbations were frequent in the course of treat-
ment. Trials of localized therapy, especially for oral GvHD, 
are warranted as a first-line response to symptom aggravation 
in order to minimize treatment-related complications.
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